Hems and hers health is down over 50% from all time highs. Still read here to date, but it's one of my favorite opportunities in the market right now, because I think the technicals are setting up for a massive breakout in the fundamental tailings are aligning. First of all, why is the stock down so much in the first place? And it's simply because we had revenue deceleration in the business whenever the GLP-1 compounded product came off the shortage list. Pair of the revenue deceleration with the acquisition of Eucalyptus, which is the overseas telehealth company they just bought, plus the restructuring cost that hit in Q-1, that's what put a lot of pressure on the stock. What's important to realize here about the revenue growth in Q-1 is that it's not going to be staying the same. Revenue recelerations come in in the back half of the year, and the company's raised guidance to $2.8 to $3 billion, which would imply around a 22 to 25% growth rate. Top of that, their international expansion of Eucalyptus just went through and they're not going to be not just a telehealth company that's based in the United States, but they're going to be expanding world-wide with the acquisition they just did. They're going to be opening up a whole new network of products and customers they're going to be able to serve. One of the things I'm most excited about with Hems and hers is the opportunity to capitalize on the peptide market. They're one of the only companies in the United States that actually has a peptide compounding facility. So the FDA is having a meeting July 23rd to July 24th. We're going to be getting more information on peptide regulation. So this is going to be something that's super bullish for Hems. If this deregulation passes and they're able to start selling peptides, they're 2.6 million subscribers. You're getting all that at a dirt cheap valuation in my opinion. The company did just over 2.3 billion dollars of revenue in 2025, targeting 6.5 billion by 2030, which would be just over a 22% revenue category from here. And you're paying just over a two times price of sales for this company that has massive global expansion opportunity and revenue growth that's going to be re-accelerated back after the year. Not to even mention the peptide opportunity they have. As the CEO of 74 on earnings calls, he views this company as a Netflix of healthcare opportunity. That's exactly what I see as well, especially just a 6 billion dollar market cap. I think this could easily become a 20 to 30 billion dollar company over the next handful of years if management's able to execute.